Cyclodextrin based therapeutic - CTD Holdings

Drug Profile

Cyclodextrin based therapeutic - CTD Holdings

Alternative Names: HP-Beta-CD - CTD Holdings; HP-β-CD - CTD Holdings; Hydroxypropyl-beta-cyclodextrin - CTD Holdings; Trappsol Cyclo; Trappsol® Hydroxypropyl Beta Cyclodextrin-Endotoxin Controlled (THPB-EC) grade - CTD

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator CTD Holdings
  • Class Beta-Cyclodextrins
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick disease type C
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Niemann-Pick disease type C
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Niemann-Pick disease type C
  • Research Diabetic nephropathies; Peripheral arterial disorders; Viral infections

Most Recent Events

  • 17 Jan 2017 Cyclodextrin based therapeutic - CTD Holdings receives Fast Track designation for Niemann-Pick disease type C [Parenteral,Liquid] in USA
  • 21 Dec 2016 CTD Holdings files a Clinical Trial Application with the Agenzia Italiana del Farmaco (AIFA) in Italy for Niemann-Pick disease type C
  • 10 Nov 2016 Swedish Medical Products Agency approves CTA application for cyclodextrin based therapeutic in Niemann-Pick disease Type C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top